512.8

-2.31%↓

SANES

10.014

-2.09%↓

BBVA

19.155

-3.55%↓

BNP

89.34

-1.62%↓

CABK

10.005

-4.62%↓

512.8

-2.31%↓

SANES

10.014

-2.09%↓

BBVA

19.155

-3.55%↓

BNP

89.34

-1.62%↓

CABK

10.005

-4.62%↓

512.8

-2.31%↓

SANES

10.014

-2.09%↓

BBVA

19.155

-3.55%↓

BNP

89.34

-1.62%↓

CABK

10.005

-4.62%↓

512.8

-2.31%↓

SANES

10.014

-2.09%↓

BBVA

19.155

-3.55%↓

BNP

89.34

-1.62%↓

CABK

10.005

-4.62%↓

512.8

-2.31%↓

SANES

10.014

-2.09%↓

BBVA

19.155

-3.55%↓

BNP

89.34

-1.62%↓

CABK

10.005

-4.62%↓

Home・Akcijų sąrašas・AB Science SA

AB Science SA

Uždarymo kaina

1.328 1.68

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.3

Max

1.33

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-5.2M
Pardavimai	515K
Pelno marža	-1,005.243
Darbuotojai	36
EBITDA	-2.5M

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-11

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	91M
Ankstesnė atidarymo kaina	-0.35
Ankstesnė uždarymo kaina	1.328

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

1.426 / 1.448 Palaikymas ir pasipriešinimas

AB Science SA Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-15 23:21; UTC

Įsigijimai, susijungimai, perėmimai

Qube Agrees to Takeover by MAM-Led Consortium Valuing Its Equity at $6.51 Billion

2026-02-15 23:45; UTC

Rinkos pokalbiai

Nikkei May Rise as Fears About AI Disruption Recede -- Market Talk

2026-02-15 23:40; UTC

Rinkos pokalbiai

Gold Falls on Possible Position Adjustments -- Market Talk

2026-02-15 23:06; UTC

Uždarbis

Thai Beverage: Spirits, Beer Businesses Posted Satisfactory EBITDA Growth, Alongside Profit Margin Expansion>Y92.SG

2026-02-15 23:04; UTC

Uždarbis

Thai Beverage 1Q Beer Business EBITDA THB4.64B, Up 4.7% on Year>Y92.SG

2026-02-15 23:04; UTC

Uždarbis

Thai Beverage 1Q Spirits Business EBITDA THB8.50B, Up 6.9% on Year >Y92.SG

2026-02-15 23:01; UTC

Uždarbis

Thai Beverage 1Q EBITDA THB16.75B, Up 1.8% on Year >Y92.SG

2026-02-15 23:01; UTC

Uždarbis

Thai Beverage 1Q FY Sales Revenue THB86.70B, Down 6.0% on Year>Y92.SG

2026-02-15 22:58; UTC

Uždarbis

Warner Bros. Lands Ninth Straight Box Office Winner With 'Wuthering Heights' -- Barrons.com

2026-02-15 22:53; UTC

Įsigijimai, susijungimai, perėmimai

Qube: MAM-Led Offer Implies A$11.7 Billion Enterprise Value

2026-02-15 22:53; UTC

Įsigijimai, susijungimai, perėmimai

Qube: UniSuper to Transfer 15.07% Stake to Equivalent Ownership of Consortium Holding Structure

2026-02-15 22:52; UTC

Įsigijimai, susijungimai, perėmimai

Qube Shareholders to Receive A$5.20/Share in Cash

2026-02-15 22:52; UTC

Įsigijimai, susijungimai, perėmimai

Qube Holdings Agrees to Takeover by Macquarie Asset Management-Led Consortium

2026-02-15 21:35; UTC

Uždarbis

Warner Bros. Lands Ninth Straight Box Office Winner With 'Wuthering Heights' -- Barrons.com

2026-02-15 20:48; UTC

Uždarbis

BlueScope: Will Now Target Net Debt of Up to A$1.5 Billion; Will Surpass as Needed

2026-02-15 20:47; UTC

Uždarbis

BlueScope: Expects Full Benefits of Further A$150M Cost Savings in FY 2027

2026-02-15 20:46; UTC

Uždarbis

BlueScope: Recorded Net Annualized Cost Improvements of A$190 Million in 1H

2026-02-15 20:45; UTC

Uždarbis

BlueScope Expects a One-Third Lower 2H Result From Asia Business Vs 1H

2026-02-15 20:44; UTC

Uždarbis

BlueScope Expects 15% Higher 2H Result From North America Business Vs 1H

2026-02-15 20:44; UTC

Uždarbis

BlueScope Expects Lower 2H Result From Australia Business Vs 1H

2026-02-15 20:43; UTC

Uždarbis

BlueScope Expects 2H Underlying Ebit of A$620 Million-A$700 Million

2026-02-15 20:42; UTC

Uždarbis

BlueScope Net Debt A$2.2 Million at Dec. 31

2026-02-15 20:42; UTC

Uždarbis

BlueScope 1H Underlying Ebit A$557.5 Million, Up 81% On-Year

2026-02-15 20:41; UTC

Uždarbis

BlueScope 1H Underlying Ebitda A$915.3 Million, Up 39% On-Year

2026-02-15 20:40; UTC

Uždarbis

BlueScope 1H Underlying Profit A$382.0 Million Vs A$176.4 Million Year Prior

2026-02-15 20:40; UTC

Uždarbis

BlueScope 1H Sales Revenue From Continuing Ops A$8.22 Billion, Up 4% On-Year

2026-02-15 20:39; UTC

Uždarbis

BlueScope Intends to Spend A$310 Million on Buyback, Or Other Returns if Share Repurchases Limited

2026-02-15 20:38; UTC

Uždarbis

BlueScope Targeting A$1.30/Share Annual Ordinary Dividend

2026-02-15 20:37; UTC

Uždarbis

BlueScope Targeting Shareholder Returns of A$3.00/Share in 2026

2026-02-15 20:37; UTC

Uždarbis

BlueScope Interim Dividend 65 Australian Cents/Share

Akcijų palyginimas

Kainos pokytis

AB Science SA Prognozė

Bendras įvertinimas

By TipRanks

0 ratings

Pirkti

Laikyti

Parduoti

Remiantis 0 analitikų, pateikusių AB Science SA akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

1.426 / 1.448Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę AB Science SA

AB Science S.A., a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company's lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer's disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19. It also developing AB8939, a microtubule destabiliser for acute myeloid leukemia. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.